Adam Reese, MD
Urology · Philadelphia, PANPI 1225158108
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $976 of the $1,419 with a category attached, or 68.8%. 7 manufacturers reported payments, led by C. R. Bard, Inc. & Subsidiaries at 47.6% of the total. Reporting peaked in 2022 at $926 and has fallen 67.6% since, to $300 in 2025. That places this record below the midpoint for urology clinicians in PA, where the typical reported total is $2,187.
Across 13 payments — averaging $109.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- C. R. Bard, Inc. & Subsidiaries$676
- Davol Inc.$300
- Tersera Therapeutics LLC$250
- Tesaro, Inc.$111
- Boston Scientific$46
- GSK$21
- plus $15 from 1 others
What the payments were for
- Consulting fees$25018%
- Speaking & faculty fees$97669%
- Food & beverage$19314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| C. R. Bard, Inc. & Subsidiaries | 1 | $676 |
| Davol Inc. | 1 | $300 |
| Tersera Therapeutics LLC | 1 | $250 |
| Tesaro, Inc. | 6 | $111 |
| Boston Scientific | 2 | $46 |
| GSK | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
How this compares
$1,419 in reported general payments places this provider in the 35th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 31 | $15,603 |
| Oxybutynin Chloride ErOxybutynin Chloride | 83 | $2,048 |
| Tamsulosin Hcl | 149 | $1,639 |
| Finasteride | 106 | $1,183 |
| Ciprofloxacin Hcl | 51 | $43 |
| Oxycodone Hcl | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.